Devens, MA – Bristol Myers Squibb (BMS) announced that the U.S. Food and Drug Administration (FDA) has approved commercial production at the company’s newest cell therapy manufacturing facility in Devens. The Devens site is a critical component of BMS’ expanding global cell therapy manufacturing footprint for long-term supply of the company’s cell therapy portfolio.
“The Devens facility integrates the latest state-of-the-art technology in the industry with top talent in the Boston area that will take us into the next phase of our cell therapy journey,” said Karin Shanahan, executive vice president, Global Product Development & Supply, BMS. “We are working diligently to increase our product capacity through new sites like Devens and by implementing innovative manufacturing solutions that help patients in need.”
“Bristol Myers Squibb’s vision of putting more patients on a path to potential cure starts with delivering on the promise of our current product portfolio and future pipeline,” said Lynelle Hoch, senior vice president, global cell therapy franchise lead, BMS. “Today’s approval underscores our commitment to deliver our transformational CAR T cell therapies to more patients.”
The new 244,000sf cell therapy manufacturing facility represents the second significant expansion of BMS’ 89-acre Devens site, which has been developing, producing, and testing clinical and commercial medicines for over a decade, and will create over 500 new cell therapy jobs. BMS also operates two R&D facilities in Cambridge and will bring these two sites together into a new building at Cambridge Crossing later in 2023.
Devens adds to the company’s global network of three state-of-the-art cell therapy manufacturing facilities in Bothell, Wash.; Warren, N.J.; and Summit, N.J., with another manufacturing site in development in Leiden, Netherlands. BMS also recently announced the addition of a new manufacturing facility and its operations for in-house viral vector production in Libertyville, Ill.